Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda’s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $221M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Longevity ... | longevity.... |
| - | Longevity ... | lvf.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.08.2022 | Series C | $123M | - |
| 11.06.2021 | Series B | $98M | - |
Mentions in press and media 9
| Date | Title | Description |
| 22.08.2022 | Senda Biosciences Raised $123M, ThreatX Got $30M, and More Boston Tech News | Photo: ThreatX / LinkedIn There was no shortage of funding news in the Boston tech scene last week. Venture dollars poured into a wide range of companies in biotech, cybersecurity and more. Read on to see who’s hiring and find out how these... |
| 16.08.2022 | Senda Biosciences Closes $123M Series C Financing | Senda Biosciences, a Cambridge, MA-based company that leverages nature to program targeted, potent, and tunable medicines, raised $123M in Series C funding. The round was led by Flagship Pioneering, with participation from Samsung Life Scie... |
| 16.08.2022 | Senda Biosciences Completes $123M Series C | CAMBRIDGE, MA, Senda Biosciences today announced the completion of a $123 million Series C financing. >> Click here for more funding data on Senda Biosciences >> To export Senda Biosciences funding data to PDF and Excel, cli... |
| 26.01.2022 | Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology | CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vi... |
| 11.06.2021 | Senda Biosciences Closes $98M Series B Financing | Senda Biosciences, a Cambridge, Mass.-based company that harnesses the molecular interactions between humans, plants, and bacteria to develop new types of medicines, raised a $55m Series B extension financing, bringing its total Series B fu... |
| 10.06.2021 | Senda Biosciences Announces Closing of $98 Million Series B Financing | |
| 10.06.2021 | Senda Biosciences : Announces Closing of $98 Million Series B Financing | CAMBRIDGE, Mass., June 10, 2021 /PRNewswire/ -- Senda Biosciences, a company that is systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of... |
| 07.01.2021 | Senda Biosciences Announces Formation of World-Class Scientific Advisory Board | |
| - | 13 самых больших инвестиций недели | Главное на 2.3 миллиарда долларов. Обзор самых крупных инвестиционных раундов прошедшей недели в мире. Авиасейлз для богатых, Убер для очень богатых, программируемые лекарства, творческий маркетинг и многое другое. 0 Обсудить 55 просмотров ... |